Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3147)	11/7/2020 5:39:27 PM
From: A.J. Mullen	Read Replies (2) \| Respond to of 3557

Pharmaceuticals are only sold on an open market when the IP is exhausted. The Bayh-Dole Act was designed to commercialize IP originating in universities. catalyst.phrma.org The march-in rights provision has never been used in practice. I'm a stockholder yet it seems reasonable to me that if taxpayers shared the to the tune of $450m, then there should be some provision guarding the interests of those taxpayers. It seems odd that there's an exception for Regeneron. It might mean nothing but slackness on the part of Warp-speed lawyers and over-zealousness by those for Regeneron. I've been very happy with the profits generated by other small companies that successfully brought drugs to the market. Egregious profits by a few companies threaten to bring heavy-handed intervention that could kill a flock of golden-egg laying geese.